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Objective:  Attention  deficit  hyperactiv-
ity disorder (ADHD) is a common, highly 
heritable psychiatric disorder. Because of 
its multifactorial etiology, however, iden-
tifying the genes involved has been diffi-
cult. The authors followed up on recent 
findings  suggesting  that  rare  copy  num-
ber variants (CNVs) may be important for 
ADHD etiology.
M ethod:  The  authors  performed  a  ge-
nome-wide  analysis  of  large,  rare  CNVs 
(<1%  population  frequency)  in  children 
with ADHD (N=896) and comparison sub-
jects (N=2,455) from the IMAGE II Consor-
tium.
Results: The authors observed 1,562 indi-
vidually rare CNVs >100 kb in size, which 
segregated  into  912  independent  loci. 
Overall, the rate of rare CNVs >100 kb was 
1.15 times higher in ADHD case subjects 
relative to comparison subjects, with du-
plications  spanning  known  genes  show-
ing a 1.2-fold enrichment. In accordance 
with a previous study, rare CNVs >500 kb 
showed  the  greatest  enrichment  (1.28-
fold). CNVs identified in ADHD case sub-
jects  were  significantly  enriched  for  loci 
implicated  in  autism  and  in  schizophre-
nia.  Duplications  spanning  the  CHRNA7 
gene at chromosome 15q13.3 were asso-
ciated with ADHD in single-locus analysis. 
This finding was consistently replicated in 
an  additional  2,242  ADHD  case  subjects 
and 8,552 comparison subjects from four 
independent  cohorts  from  the  United 
Kingdom, the United States, and Canada. 
Presence  of  the  duplication  at  15q13.3 
appeared to be associated with comorbid 
conduct disorder.
Conclusions: These findings support the 
enrichment of large, rare CNVs in ADHD 
and  implicate  duplications  at  15q13.3 
as  a  novel  risk  factor  for  ADHD.  With  a 
frequency  of  0.6%  in  the  populations 
investigated  and  a  relatively  large  effect 
size  (odds  ratio=2.22,  95%  confidence 
interval=1.5–3.6), this locus could be an 
important contributor to ADHD etiology.
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sociated with ADHD, a finding that was replicated in an 
additional 825 patients and 35,243 comparison subjects. 
The most recent study (18) investigated 248 children with 
ADHD and their parents and observed de novo CNVs in 
1.7% of the children and inherited CNVs in genes previ-
ously linked to ADHD or other neurodevelopmental dis-
orders in 8%.
In this study, we followed up on these findings by per-
forming a genome-wide analysis of CNVs in 896 children 
with ADHD and 2,455 unrelated comparison subjects col-
lected as part of the IMAGE II Consortium genome-wide 
association study (8), which represents the largest collec-
tion of ADHD cases studied to date.
Method
Participants
The 896 case subjects investigated in this study consisted of 
1) samples collected by a subset of the International Multicenter 
ADHD Genetics (IMAGE) Project sites but not included in the 
IMAGE GWAS (7) and 2) samples collected at additional sites in 
the United Kingdom, Ireland, Germany, Switzerland, the Nether-
lands, and the United States and were assessed in a manner simi-
lar to that of the IMAGE samples. Case subjects were of European 
origin. At the collection sites, patients had been identified mainly 
through outpatient clinics, met DSM-IV criteria for ADHD, had 
been referred for assessment of hyperactive, disruptive, or dis-
organized behavior, and had been clinically diagnosed as having 
ADHD (or hyperkinetic disorder, the most closely equivalent cat-
egory in the ICD-10 nomenclature used by some of the clinics) 
using semistructured interviews with parents. All sites excluded 
subjects with an IQ below 70. The characteristics of the full case 
sample have been described in detail elsewhere (8); the charac-
teristics of the sample included in the final analysis of the present 
study are summarized in Table S1 in the online data supplement 
that accompanies the online edition of this article. Twenty-three 
cases overlap with a recent CNV analysis by Williams et al. (17); 99 
cases overlap with another CNV analysis using array comparative 
genomic hybridization technology (16). Results from these over-
lapping cases are clearly marked in Table S4 in the data supple-
ment. For 600 cases, additional data on ADHD subtype and sever-
ity as well as presence of comorbid oppositional defiant disorder 
or conduct disorder were available. All case data were collected 
with the informed consent of parents and with the approval of 
each site’s institutional review board or ethical committee.
The comparison samples (2,455 population subjects of Euro-
pean ancestry) were collected for a GWAS of schizophrenia and 
have  been  described  elsewhere  (19).  Briefly,  the  comparison 
subjects were drawn from a nationally representative U.S. sur-
vey  panel  ascertained  via  random  digit  dialing.  Subjects  were 
screened for psychosis and bipolar disorder but not for ADHD. 
A blood sample was collected via phlebotomy services. Compari-
son subjects gave written consent for their biological materials 
to be used for medical research at the discretion of the National 
Institute of Mental Health.
Replication analysis was performed for the most frequent find-
ing on chromosome 15q13. Replication samples included those 
from the recently published CNV study from Cardiff, U.K., exclud-
ing the 23 ADHD cases that overlap with the IMAGE II discovery 
sample (296 DSM-IV ADHD case subjects with IQ >70 and 1,047 
comparison subjects genotyped on Illumina Human660W-Quad 
BeadChip [for the case subjects] or HumanHap550 BeadChip [for 
the comparison subjects]) (17); from the PUWMa (Pfizer-funded 
Attention deficit hyperactivity disorder (ADHD) is one 
of the most common neuropsychiatric disorders in chil-
dren (seen in 3%–5% of school-age children) (1) and adults 
(2%–4%) (2). Twin and adoption studies have shown high 
heritability of ADHD, with estimates averaging 76% (3). 
The etiology of ADHD is complex, with contributions from 
both genes and environmental factors. Until recently, re-
search on the genetics of ADHD has focused mainly on 
common genetic variants in candidate gene studies. The 
effect sizes of most associated genetic variants identified 
have been small (4, 5). The few genome-wide association 
studies (GWAS) performed so far have been too under-
powered to observe genome-wide significant associations 
(6–11), which fits well with the view of ADHD as a poly-
genic,  multifactorial  disorder,  to  which  many  common 
DNA variants (and environmental factors) of small effect 
contribute.
In  contrast  to  this  common  disease-common  variant 
hypothesis, rare genetic variants of moderate to large ef-
fect size have been found in a proportion of case subjects 
with  other  psychiatric  disorders,  such  as  schizophrenia 
and autism (12). So far, most such variants have been chro-
mosomal aberrations and copy number variants (CNVs), 
deletions and duplications that encompass relatively large 
genomic  segments  spanning  1  kb  to  several  megabases 
in size. Depending on their location, CNVs can influence 
gene expression through gene dosage effects or can di-
rectly influence protein function by excising or duplicating 
functional domains.
In  ADHD,  large,  rare  chromosomal  aberrations  have 
been reported to increase the risk for ADHD—for example, 
through  the  22q11  deletion  syndrome  (40%–45%  of  pa-
tients with this syndrome have ADHD) [13]—as have rare 
chromosomal  alterations,  including  a  translocation  in-
volving SLC9A9 cosegregating with ADHD in an extended 
pedigree (14). The first published genome-wide analysis of 
CNVs in ADHD, which studied 335 ADHD child-parent tri-
os and 2,026 healthy comparison subjects, failed to identi-
fy significant evidence for a higher rate of CNVs in patients 
(15). The study did, however, describe a number of the rare 
CNVs identified in ADHD patients, which spanned some 
intriguing candidate genes. A relatively large number of 
the CNVs occurred at loci that had previously been impli-
cated in other disorders, especially autism, schizophrenia, 
and Tourette’s syndrome. A second CNV study analyzed 
99 ADHD patients (16) and identified a duplication of the 
neuropeptide Y  gene  (NPY)  cosegregating  with  disease 
in an extended pedigree. A recent genome-wide study of 
CNVs in ADHD (17), in which 366 children with ADHD and 
1,047 comparison subjects were analyzed, found evidence 
for an overall increased burden of large, rare CNVs in the 
ADHD patients, which were also significantly enriched at 
loci that had previously been implicated in autism and 
schizophrenia. Moreover, locus-specific analysis revealed 
significant evidence that duplications at 16p13.11 were as-WilliAMS, FrANKE, MiCK, Et Al.
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subjects with the duplication (control carriers), and four random 
comparison  subjects  (non-ADHD). The  characteristics  of  each 
subject are summarized in Table S2 in the online data supple-
ment, and procedures are explained in Table S3.
Replication of Duplications at 15q13.3
The eight duplications identified in the ADHD patient sam-
ple  at  15q13.3  spanned  a  consensus  region  of  approximately 
420 kb that was clearly defined by two segmental duplications 
(chr15:29,811,982–30,232,981,  National  Center  for  Biotechnol-
ogy Information Build 36.1-hg18). From each replication cohort, 
we selected all duplications in the case and comparison subjects 
that spanned the 15q13.3 consensus region by at least 60%. Tests 
of association were then performed for each replication sample 
by Fisher’s exact test and for meta-analysis by logistic regression 
with sample site included as an independent variable. The Bres-
low-Day test was used to test for heterogeneity between replica-
tion samples.
results
A total of 732 ADHD cases passed quality control; 84% 
of subjects were male, and the mean age was 10.4 years. 
Most had combined-type ADHD (81%), and the remain-
der had primarily inattentive (14%) or primarily hyperac-
tive-impulsive ADHD (5%). In the subsample for which 
information  on  comorbid  disorders  was  available,  18% 
had comorbid conduct disorder and 47% had comorbid 
oppositional  defiant  disorder.  A  detailed  breakdown  by 
site has been described (8) and is summarized in Table 
S1 in the online data supplement. After exclusion of com-
mon (minor allele frequency >0.01) CNVs, all association 
analyses were based on 1,562 rare CNVs larger than 100 
kb (460 in case subjects and 1,102 in comparison subjects; 
see Table S4 in the online data supplement). There was no 
significant difference in the rate at which CNVs >100 kb 
were called in males compared with females in either case 
or comparison subjects (data not presented).
We observed a significant excess of rare CNVs >100 kb in 
our ADHD case subjects relative to comparison subjects, 
with a rate 1.15 times higher and a proportion of subjects 
carrying at least one rare CNV >100 kb 1.13 times higher 
(Table  1). There  was  no  significant  evidence  to  suggest 
that the rare CNVs identified in the ADHD cases were on 
average longer than those identified in the comparison 
subjects, a finding in line with that of a previous study us-
ing a different data set (17). Limiting our analysis to the 
largest CNVs suggested that the higher rate in ADHD cases 
was strongest for rare CNVs >500 kb (1.28 times higher in 
the ADHD cases, p=0.032; Table 1). The rate of rare CNVs 
>500 kb observed in ADHD cases was 12.2%, which is in 
accordance with the rate of 12.5% reported in the previous 
study using analogous methodology and a different data 
set (17). While there was a difference in the gender dis-
tribution between the ADHD cases and the population-
based comparison sample (which was 48% male), there 
was no significant difference in the rate at which CNVs 
>100 kb were called in males compared with females in 
either case or comparison subjects (data not presented). 
When  we  restricted  the  analysis  to  CNVs  >100  kb  that 
study  from  UCLA,  Washington  University,  and  Massachusetts 
General  Hospital)  sample  of  692  DSM-IV  ADHD  case  subjects 
and 1,101 comparison subjects genotyped on the Illumina 1M 
BeadChip as described elsewhere (9); from a Canadian study that 
included 247 DSM-IV ADHD case subjects and 2,357 comparison 
subjects genotyped on the Affymetrix 6.0 array (18); and from 
an unpublished sample that included 1,013 DSM-IV ADHD case 
subjects and 4,105 comparison children genotyped on the Illumi-
na Infinium HumanHap550K BeadChip at Children’s Hospital of 
Philadelphia. In the latter study, ADHD case subjects of Northern 
European descent (ages 6–18) were recruited from pediatric and 
behavioral health clinics in the Philadelphia area. Exclusionary 
criteria  included  prematurity  (<36  weeks),  mental  retardation, 
major medical or neurological disorders, pervasive developmen-
tal disorder, psychosis, and major mood disorders.
Statistical Analysis of Rare CNV Data
Quality control for samples, the procedures for CNV calling, 
and quality control for the CNV calls are described in the online 
data supplement. The genome-wide burden of rare CNVs was as-
sessed according to either the number of rare CNVs per sample 
or the average rare CNV size per sample. Gene-centric burden 
analysis was performed by limiting the analysis to rare CNVs that 
overlapped with the list of genes (defined according to +/– 50 kb 
of the largest transcript) present in National Center for Biotech-
nology Information Build 36.1-hg18 (http://pngu.mgh.harvard.
edu/~purcell/plink/res.shtml#glist).  In  accordance  with  other 
studies, the significance of the burden comparisons was assessed 
via  permutation  (10,000  permutations,  one-sided  test)  using 
PLINK  (http://pngu.mgh.harvard.edu/~purcell/plink).  Analyses 
were performed for all large, rare CNVs as well as by stratification 
according to CNV type (deletion or duplication) and size (>100 kb 
or >500 kb). Differences in the rates at which CNVs were called in 
males or females were assessed separately in case and compari-
son subjects using PLINK, with significance assessed via permu-
tation (10,000 permutations, two-sided test).
To perform locus-specific tests of association, we first defined 
test regions according to the genomic boundaries for each CNV 
identified in the entire sample. Where multiple CNVs identified in 
different samples overlapped, they were merged to create a single 
locus that encompassed all overlapping CNVs. PLINK was then 
used to determine the number of CNVs present within each test 
region in case and comparison subjects. Locus-specific tests of 
association were made using PLINK, again with the significance 
being assessed via permutation (10,000 permutations, one-sided 
test).
To assess whether the CNVs identified in our ADHD cohort were 
significantly  enriched  for  loci  previously  implicated  in  schizo-
phrenia or autism, we first defined the genomic coordinates for 
a list of single genes and genomic regions containing contiguous 
sets of genes that had previously been reported to harbor CNVs 
associated  with  a  greater  risk  of  autism  (20)  or  schizophrenia 
(21–25). We then counted the number of CNVs larger than 100 
kb in the case and comparison subjects that occurred within, or 
completely or partially overlapped, each locus. We also tested the 
overall significance of case-control comparisons for the total bur-
den of CNVs at these loci using logistic regression analysis. To al-
low for the possibility that any significant overlap was caused by 
differences in the size of CNVs in the case and comparison sub-
jects, we included CNV size as an independent variable.
Validation of a Rare CNV on 15q13.3
A total of 41 subjects were included in the validation study us-
ing quantitative real-time polymerase chain reaction analysis, in-
cluding eight ADHD 15q13.3 duplication carriers (ADHD carriers) 
and their family members, eight randomly selected ADHD sub-
jects without duplications (ADHD noncarriers), six comparison CoPY NUMBEr VAriANtS iN AttENtioN DEFiCit HYPErACtiVitY DiSorDEr
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Caucasian  descent  from  the  United  States,  the  United 
Kingdom, and Canada (Table 2). Duplications spanning 
chr15:29,811,982–30,232,981 were found in case and com-
parison subjects from all samples (Figure 1), and they were 
indeed enriched in the ADHD patients across the replica-
tion samples (p=0.00275; Table 2). Combined analysis of 
all samples investigated (2,966 cases, 10,556 comparison 
subjects) produced highly significant evidence that dupli-
cations at 15q13.3 are associated with ADHD (p=0.000178; 
odds ratio=2.22, 95% confidence interval=1.46–3.38).
It was previously reported that CNVs identified in ADHD 
cases  are  enriched  at  loci  that  harbor  CNVs  associated 
with schizophrenia and autism (17). In the present study, 
we observed that 18 of 460 (3.9%) CNVs >100 kb identi-
fied in the case subjects overlapped with one of the 32 loci 
previously implicated in autism (20), compared with only 
20 of 1,102 (1.8%) of the CNVs identified in comparison 
subjects (p=0.009; Table 3), representing a rate 2.16 times 
greater in case subjects relative to comparison subjects. 
We also observed that ADHD case subjects had a 1.49-fold 
excess of CNVs located at the eight loci previously impli-
cated  in  schizophrenia  relative  to  comparison  subjects 
(5.4% compared with 3.6%, p=0.03; Table 3). The lists of re-
gions previously implicated in autism and schizophrenia 
are not independent of each other (they have five regions 
in common).
Discussion
Until  recently,  the  common  disease-common  variant 
hypothesis  has  been  used  to  explain  the  occurrence  of 
most cases of psychiatric disorders. Recent studies show-
ing a higher frequency of rare CNVs in psychiatric patients 
have challenged this view. Such rare CNVs have also been 
described in ADHD patients (15, 16, 18) and have been 
spanned genes, we found a significantly greater burden of 
such CNVs in case subjects, which was strongest for du-
plications (Table 1). There was no evidence of a greater 
burden  of  non-gene-centric  CNVs  >100  kb  (minimum 
p=0.11; data not presented). As over 90% of CNVs >500 kb 
spanned at least one gene, the gene-centric burden analy-
sis was limited to CNVs >100 kb.
The 1,562 CNVs included in this study segregated into 
912  independent  loci  (see  Table  S5  in  the  online  data 
supplement). Genome-wide locus-specific analysis iden-
tified one region (chr15:28,231,568–30,571,466) that was 
nominally associated with ADHD (p=0.012), although this 
finding did not survive correction for genome-wide test-
ing (p=0.79). Nevertheless, post hoc analysis of this locus 
revealed that the association was primarily contributed to 
by eight duplications in 732 ADHD cases, compared with 
six in the 2,010 comparison subjects (p=0.016 uncorrect-
ed), all of which spanned a consensus region of approxi-
mately 420 kb (chr15:29,811,982–30,232,981), defined by 
two segmental duplications (Figure 1). Validation of the 
CNV using a different genotyping method confirmed the 
presence of the variant in the ADHD cases and showed 
that it was inherited in all families for which both parents 
were available for testing (see Figure S1 in the online data 
supplement). While post hoc analyses failed to reveal any 
significant evidence that overall CNV carriership was as-
sociated  with  ADHD  subtype,  ADHD  symptom  dimen-
sion,  or  presence  of  oppositional  defiant  disorder,  we 
did  observe  a  nominally  significant  association  (p=0.03 
uncorrected)  between  conduct  disorder  and  carriers  of 
15q13.3 duplications.
We  attempted  to  replicate  the  observation  of  an  ex-
cess  of  duplications  at  15q13.3  by  studying  an  addi-
tional  2,242  ADHD  case  subjects  and  8,552  compari-
son  subjects  in  four  independent  samples  of  European 
tABlE 1. Global Burden Analysis of rare Copy Num ber Variants (CNVs) in Children With ADHD (N=896) and Com parison 
Subjects (N=2,455) From  the iMAGE ii Consortium
Burden of CNVs Burden of Deletions Only Burden of Duplications Only
Measurea
ADHD 
Subjects
Com-
parison 
Subjects Ratio pb
ADHD 
Subjects
Com-
parison 
Subjects Ratio pb
ADHD 
Subjects
Com-
parison 
Subjects Ratio pb
CNVs >100 kb
  N 460 1,102 161 406 299 696
  Rate 0.628 0.548 1.15 0.014 0.220 0.202 1.09 0.199 0.409 0.346 1.18 0.016
  Proportion 0.456 0.406 1.13 0.011 0.194 0.179 1.09 0.197 0.327 0.282 1.16 0.014
CNVs >500 kb
  N 89 191 22 47 67 144
  Rate 0.122 0.095 1.28 0.032 0.030 0.023 1.29 0.199 0.092 0.072 1.28 0.059
  Proportion 0.112 0.092 1.22 0.069 0.030 0.023 1.29 0.199 0.085 0.070 1.21 0.113
CNVs >100 kb, 
intersecting genes
  N 303 720 74 203 229 517
  Rate 0.414 0.358 1.16 0.025 0.101 0.101 1.00 0.524 0.313 0.257 1.22 0.013
  Proportion 0.329 0.290 1.14 0.031 0.097 0.092 1.06 0.359 0.262 0.219 1.20 0.010
a N=the number of CNVs observed; rate=the average number of CNVs per person; proportion=the proportion of samples carrying at least one 
CNV.
b Empirical and one-sided p values.WilliAMS, FrANKE, MiCK, Et Al.
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chance, and they share heritability (27). The overlap in 
CNV loci among disorders suggests pleiotropy of genes 
predisposing to psychiatric disorders (28–31). Additional 
factors seem to be necessary to explain the specificity of 
a clinical phenotype. On the other hand, pleiotropy might 
also imply that the clinical classification tools for psychi-
atric disorders do not match the biological underpinnings 
of such disorders (28).
In this study, we were also able to perform a regional 
analysis  testing  each  locus  carrying  a  CNV  for  associa-
tion with ADHD. Despite earlier identification of ADHD 
case subjects carrying duplications at 16p13 (17), in this 
sample  there  was  no  evidence  for  association  between 
duplications  at  this  locus  and  ADHD  (two  CNVs  were 
found in case subjects, six in comparison subjects). How-
ever, we did identify significant associations of duplica-
tions at 15q13.3 with ADHD. Notably, we replicated this 
observation in a total of 2,242 independent ADHD cases 
and 8,552 comparison subjects from four different sites, 
including the study by Stergiakouli et al. (32). Duplications 
were identified at 15q13.3 in all studies and using all dif-
ferent platforms for CNV detection used, with odds ratios 
found to be enriched in this population (17). Our results 
in this study, a CNV analysis in the largest clinical sample 
hitherto investigated, support the findings of the previous 
study (17) reporting an increased burden of rare CNVs in 
ADHD patients. Whereas the latter study investigated only 
CNVs  larger  than  500  kb  (showing  enrichment  in  both 
deletions and duplications in the patients), we show here 
that  an  increased  burden  is  also  observed  when  CNVs 
down to 100 kb in size are considered.
While most CNVs occurred only in single patients in 
our study, there was some overlap with the findings from 
the earlier CNV studies in ADHD (15–18), and some CNVs 
have been linked to ADHD in other ways (see Table S6 
in the online data supplement). These CNVs mark genes 
that might be of particular relevance to ADHD and would 
make good candidates for further study.
As also noted in earlier CNV studies in ADHD (15–17), 
we found significant evidence that CNV regions in ADHD 
patients overlapped with loci implicated by CNVs in au-
tism  and  schizophrenia.  Although  schizophrenia  and 
ADHD do not typically co-occur, ADHD and autism co-
occur in patients more often than would be expected by 
FiGUrE 1. representation of the Duplications at 15q13.3 Found in the Discovery Sam ple (iMAGE ii) and All replication 
Sam plesa
Scale chr15bp:
26000000 26500000 27000000 27500000 28000000 28500000 29000000 29500000 30000000 30500000 31000000
15q13.3 15q13.2
Duplications in Replication Samples – ADHD Case Subjects
Duplications in Replication Samples – Comparison Subjects
Segmental Duplications
RefSeq Genes
CHRNA7 KLF13
TRPM1
FAN1
MTMR10
LOC283710
APBA2
FAM189A1
NDNL2
TJP1
Duplications in IMAGE2 Sample – Comparison Subjects
Duplications in IMAGE2 Sample – ADHD Case Subjects
Chromosome Bands Localized by FISH Mapping Clones
2 Mb
15q13.1
a Segmental duplications are labeled using the nomenclature defined by Szafranski et al. (26). FISH=fluorescent in situ hybridization.CoPY NUMBEr VAriANtS iN AttENtioN DEFiCit HYPErACtiVitY DiSorDEr
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tified  in  ADHD  behave  as  highly  penetrant  variants,  as 
overlap is routinely observed in findings between patients 
and comparison subjects. From this, we can conclude that 
these CNVs are neither necessary nor sufficient to cause 
ADHD. This is consistent with other studies of rare CNVs 
segregating in extended pedigrees, which did not report 
perfect cosegregation of risk variants with ADHD (16, 39) 
or autism (40). Therefore, while we accept that particularly 
for de novo variants we cannot exclude a high penetrance, 
we expect that most rare CNVs implicated in this and oth-
er studies are moderate risk factors for ADHD that interact 
with other DNA risk variants or environmental factors to 
cause the disorder.
Our study has both strengths and weaknesses. Clearly, 
the study’s large sample size is an important strength, as is 
the availability of several replication cohorts. The poten-
tial weakness of using two different genotyping platforms 
for case and comparison subjects has been addressed by 
concentrating only on SNPs represented on both arrays, 
by strict quality control, and by analysis of only large, rare 
CNVs, which, in accordance with previous findings (17, 
21), can be reliably called. Unfortunately, we could not as-
sess the inheritance of most of our rare CNVs. Finally, our 
sample is not well suited for studying additional pheno-
typic variation, given the limited phenotypic range caused 
by the fact that most case subjects suffered from the most 
severe, combined form of ADHD. Even larger studies with 
more phenotypic variability might be necessary to inves-
tigate the effects of CNVs on the ADHD subtypes and cor-
relates.
In conclusion, our study provides further evidence for 
a role of large, rare CNVs in ADHD. The replicated asso-
ciation between ADHD and duplications on chromosome 
15q13.3, increasing ADHD risk with an odds ratio of 2.22, 
is one of the strongest risk factors for ADHD identified 
thus far and, with a frequency >0.6% in the population, 
could be an important contributor to ADHD etiology.
ranging from 0.91 to 3.99. Specifically, our data implicate 
duplications spanning a region of approximately 420 kb 
(chr15:29,811,982–30,232,981),  which  is  flanked  by  two 
segmental duplications. However, as with all CNV analyses 
of single-nucleotide polymorphism (SNP) array data, our 
study had limited resolution to establish the nature of po-
tentially complex rearrangements at this locus; therefore, 
we cannot exclude the possibility that some of the dupli-
cations identified at 15q13 are of a more complex nature. 
The presence of the 15q13.3 duplication also seemed to 
modulate the ADHD phenotype, as carriers had a higher 
lifetime rate of comorbid conduct disorder.
Rare  CNVs  in  this  locus  (deletions  and  duplications) 
have previously been implicated in several psychiatric dis-
orders (e.g., autism, schizophrenia, intellectual disability), 
as well as nonpsychiatric conditions, such as epilepsy (33), 
albeit  with  reduced  penetrance.  The  duplicated  region 
contains a plausible candidate gene for ADHD, CHRNA7 
(Mendelian Inheritance in Man code *118511), which en-
codes the a7 subunit of the neuronal nicotinic acetylcho-
line receptor, a homo-oligomeric ion channel involved in 
calcium signaling in the brain. The a7 nicotinic acetylcho-
line receptor participates in an ADHD-relevant pathway 
by mediating dopamine release (34). Dopamine dysregu-
lation is strongly implicated in ADHD; in fact, a7 receptor 
agonists show modest efficacy for the treatment of ADHD 
(35). Two candidate gene studies of microsatellite mark-
ers and a SNP in and near this gene in ADHD have been 
negative (36, 37). However, a recent study implicates the 
receptor in the response to stress and shows that maternal 
genotype has a strong effect on offspring phenotype (38). 
This might suggest that this gene is a particularly interest-
ing candidate for parent-of-origin and gene-environment 
interaction studies in ADHD.
Do our findings imply that ADHD behaves as a mono-
genic disease in the patients carrying CNVs? This study 
does not provide evidence that any of the rare CNVs iden-
tABlE 2. replication Study of Duplications at 15q13.3 in Children With ADHD and Com parison Subjectsa
ADHD Subjects Comparison Subjects
Sample
15q13 
Duplica-
tion (N)
No Dupli-
cation (N)
Duplica-
tion Fre-
quency 
(%)
15q13 
Duplica-
tion (N)
No Dupli-
cation (N)
Duplica-
tion Fre-
quency 
(%) p
Odds 
Ratio 95% CI
Breslow-
Day Test
Primary study
  IMAGE II 8 724 1.10 6 2,004 0.30 0.016 3.68 1.27–10.63
Replication studies
  Cardiff 6 313 1.92 5 1,042 0.48 0.023 3.99 1.21–13.18
  Children’s Hospital of 
Philadelphia 15 998 1.50 32 4,073 0.79 0.039 1.91 1.03–3.55
  Toronto 2 245 0.82 16 2,341 0.68 0.814 1.19 0.27–5.23
  PUWMa 6 686 0.87 5 1,096 0.46 0.210 0.91 0.34–2.44
All replication samples 29 2,242 1.29 58 8,552 0.68 0.00275 2.02 1.26–3.21 0.62
All samples combined 37 2,966 1.25 64 10,556 0.61 0.000178 2.22 1.46–3.38 0.28
a In each individual sample, association was tested using Fisher’s exact test. For combined samples, association was tested using logistic re-
gression with disease group as factor, and heterogeneity was assessed using the Breslow-Day test. PUWMa=Pfizer-funded study from UCLA, 
Washington University, and Massachusetts General Hospital.WilliAMS, FrANKE, MiCK, Et Al.
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tABlE 3. overlap With Copy Num ber Variants (CNVs) identified in ADHD and loci im plicated in Autism  and Schizophreniaa
All CNVs >100 kb
Gene/Locus and Measure Chromosome Start (bp) End (bp) ADHD Subjects Comparison Subjects
Implicated in autism
NRXN1 2 50000991 51113178 0 0
SLC9A9 3 144466753 145049979 0 0
c3orf58 3 145173602 145193895 0 0
NIPBL 5 36912617 37101678 0 0
NSD1 5 176492685 176659820 0 0
AHI1 6 135646816 135860576 0 0
CNTNAP2 7 145444385 147749019 0 0
CHD7 8 61753892 61942021 0 0
VPS13B 8 100094669 100958984 0 0
TSC1 9 134756556 134809841 0 0
PTEN 10 89613174 89718512 0 0
DHCR7 11 70823104 70837125 0 0
CACNA1C 12 2032676 2677376 0 0
PTPN11 12 111340918 111432100 0 0
UBE3A 15 23133488 23235221 0 0
TSC2 16 2037990 2078714 0 0
CREBBP 16 3715056 3870122 0 0
RAI1 17 17525511 17655490 0 0
NF1 17 26446120 26728821 0 0
DMPK 19 50964815 50977655 0 0
ADSL 22 39072449 39092521 0 0
SHANK3 22 49459935 49518507 0 0
1p36 1 1 5308621 2 0
1q21.1 1 144979000 146204000 1 3
2q37 2 239619630 242951149 0 1
4p16 4 1 2043468 0 0
7q11.23 7 71970679 74254837 0 0
15q11.2–q13.1 15 21309483 26230781 2 1
15q13.3 15 28557287 30488774 9 7
15q24 15 72164227 73949332 0 0
16p11.2 16 29550000 30200000 1 4
22q11 22 17015754 20000000 3 4
CNVs overlapping 18 20
CNVs not overlapping 442 1,082
p 0.009
Frequency of CNV hits 0.039 0.018
Ratio (case/control) 2.156
Implicated in schizoprenia
CNTNAP2 7 145444385 147749019 0 0
NRXN1 2 50000991 51113178 0 0
1q21.1 1 144940000 146290000 1 3
15q11.2 15 20310000 20780000 8 13
15q13.3 15 28720000 30300000 9 7
16p13.11 16 14890000 16390000 3 9
16p11.2 16 29554844 30085308 1 4
22q11 22 17500000 20000000 3 4
CNVs overlapping 25 40
CNVs not overlapping 435 1,062
p 0.03
Frequency of CNV hits 0.054 0.036
Ratio (case/control) 1.497
a All p values calculated using logistic regression correcting for CNV size.CoPY NUMBEr VAriANtS iN AttENtioN DEFiCit HYPErACtiVitY DiSorDEr
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